160 related articles for article (PubMed ID: 31956062)
1. Drug-free in-vitro activation of follicles and fresh tissue autotransplantation as a therapeutic option in patients with primary ovarian insufficiency.
Ferreri J; Fàbregues F; Calafell JM; Solernou R; Borrás A; Saco A; Manau D; Carmona F
Reprod Biomed Online; 2020 Feb; 40(2):254-260. PubMed ID: 31956062
[TBL] [Abstract][Full Text] [Related]
2. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency.
Suzuki N; Yoshioka N; Takae S; Sugishita Y; Tamura M; Hashimoto S; Morimoto Y; Kawamura K
Hum Reprod; 2015 Mar; 30(3):608-15. PubMed ID: 25567618
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Activation of Follicles and Fresh Tissue Auto-transplantation in Primary Ovarian Insufficiency Patients.
Zhai J; Yao G; Dong F; Bu Z; Cheng Y; Sato Y; Hu L; Zhang Y; Wang J; Dai S; Li J; Sun J; Hsueh AJ; Kawamura K; Sun Y
J Clin Endocrinol Metab; 2016 Nov; 101(11):4405-4412. PubMed ID: 27571179
[TBL] [Abstract][Full Text] [Related]
4. Drug-free in-vitro activation of follicles for infertility treatment in poor ovarian response patients with decreased ovarian reserve.
Kawamura K; Ishizuka B; Hsueh AJW
Reprod Biomed Online; 2020 Feb; 40(2):245-253. PubMed ID: 31753712
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy after drug-free in vitro activation of follicles and fresh tissue autotransplantation in primary ovarian insufficiency patient: a case report and literature review.
Fabregues F; Ferreri J; Calafell JM; Moreno V; Borrás A; Manau D; Carmona F
J Ovarian Res; 2018 Aug; 11(1):76. PubMed ID: 30170634
[TBL] [Abstract][Full Text] [Related]
6. Biopsying, fragmentation and autotransplantation of fresh ovarian cortical tissue in infertile women with diminished ovarian reserve.
Lunding SA; Pors SE; Kristensen SG; Landersoe SK; Jeppesen JV; Flachs EM; Pinborg A; Macklon KT; Pedersen AT; Andersen CY; Andersen AN
Hum Reprod; 2019 Oct; 34(10):1924-1936. PubMed ID: 31593582
[TBL] [Abstract][Full Text] [Related]
7. Surgical approaches of drug-free in vitro activation and laparoscopic ovarian incision to treat patients with ovarian infertility.
Tanaka Y; Hsueh AJ; Kawamura K
Fertil Steril; 2020 Dec; 114(6):1355-1357. PubMed ID: 32907748
[TBL] [Abstract][Full Text] [Related]
8. Oocyte matched follicular fluid anti-Müllerian hormone is an excellent predictor of live birth after fresh single embryo transfer.
Ciepiela P; Dulęba AJ; Kario A; Chełstowski K; Branecka-Woźniak D; Kurzawa R
Hum Reprod; 2019 Nov; 34(11):2244-2253. PubMed ID: 31725884
[TBL] [Abstract][Full Text] [Related]
9. Maternal serum concentration of anti-Müllerian hormone is a better predictor than basal follicle stimulating hormone of successful blastocysts development during IVF treatment.
Sadruddin S; Barnett B; Ku L; Havemann D; Mucowski S; Herrington R; Burggren W
PLoS One; 2020; 15(10):e0239779. PubMed ID: 33044971
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of random start versus clomiphene citrate and gonadotropin cycles in occult premature ovarian insufficiency patients, refusing oocyte donation: a retrospective cohort study.
Hatirnaz S; Basbug A; Akarsu S; Hatirnaz E; Demirci H; Dahan MH
Gynecol Endocrinol; 2018 Nov; 34(11):949-954. PubMed ID: 29847194
[TBL] [Abstract][Full Text] [Related]
11. Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos?
Drakopoulos P; Blockeel C; Stoop D; Camus M; de Vos M; Tournaye H; Polyzos NP
Hum Reprod; 2016 Feb; 31(2):370-6. PubMed ID: 26724797
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET.
Tsakos E; Tolikas A; Daniilidis A; Asimakopoulos B
Arch Gynecol Obstet; 2014 Dec; 290(6):1249-53. PubMed ID: 25001569
[TBL] [Abstract][Full Text] [Related]
13. Use of ovarian reserve parameters for predicting live births in women undergoing in vitro fertilization.
Lukaszuk K; Kunicki M; Liss J; Lukaszuk M; Jakiel G
Eur J Obstet Gynecol Reprod Biol; 2013 Jun; 168(2):173-7. PubMed ID: 23485092
[TBL] [Abstract][Full Text] [Related]
14. Biomechanical characteristics of the ovarian cortex in POI patients and functional outcomes after drug-free IVA.
Méndez M; Fabregues F; Ferreri J; Calafell JM; Villarino A; Otero J; Farre R; Carmona F
J Assist Reprod Genet; 2022 Aug; 39(8):1759-1767. PubMed ID: 35904669
[TBL] [Abstract][Full Text] [Related]
15. The use of anti-Müllerian hormone and antral follicle count to predict the potential of oocytes and embryos.
Majumder K; Gelbaya TA; Laing I; Nardo LG
Eur J Obstet Gynecol Reprod Biol; 2010 Jun; 150(2):166-70. PubMed ID: 20223579
[TBL] [Abstract][Full Text] [Related]
16. Multi-marker assessment of ovarian reserve predicts oocyte yield after ovulation induction.
Al-Azemi M; Killick SR; Duffy S; Pye C; Refaat B; Hill N; Ledger W
Hum Reprod; 2011 Feb; 26(2):414-22. PubMed ID: 21147822
[TBL] [Abstract][Full Text] [Related]
17. Ovarian response to controlled ovarian hyperstimulation: what does serum FSH say?
Oudshoorn SC; van Tilborg TC; Hamdine O; Torrance HL; Eijkemans MJC; Lentjes EGWM; Lambalk CB; Broekmans FJM
Hum Reprod; 2017 Aug; 32(8):1701-1709. PubMed ID: 28854580
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of anti-Müllerian hormone-tailored ovarian stimulation protocols in in vitro fertilization/intracytoplasmic sperm injection cycles in women of advanced age.
Liao CC; Lee RK; Lin SY; Lin MH; Hwu YM
Taiwan J Obstet Gynecol; 2016 Apr; 55(2):239-43. PubMed ID: 27125408
[TBL] [Abstract][Full Text] [Related]
19. [Effects of cystectomy for ovary benign cyst on ovarian reserve and pregnancy outcome of in vitro fertilization-embryo transfer cycle].
Zhang XR; Ding LL; Tang R; Sheng Y; Qin YY; Chen ZJ
Zhonghua Fu Chan Ke Za Zhi; 2016 Mar; 51(3):180-5. PubMed ID: 27030496
[TBL] [Abstract][Full Text] [Related]
20. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
Hohmann FP; Macklon NS; Fauser BC
J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
